Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Costa V, Canver MC, Harris RM, Rand JH, Greenblatt MB. Accelerated thrombin times are associated with thrombotic risk. Am J Hematol. 2020;95(5):E113-E114.

Patel SS, Kluk MJ, Weinberg OK. NPM1 Biology in Myeloid Neoplasia. Curr Hematol Malig Rep. 2020;15(4):350-359.

Hadi K, Yao X, Behr JM, Deshpande A, Xanthopoulakis C, Tian H, et al. Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell. 2020;183(1):197-210.e32.

Ma LX, Craig KM, Mosquera JM, Robinson BD, Scherr DS, Del Pizzo J, et al. Contemporary Results and Clinical Utility of Renal Mass Biopsies in the Setting of Ablative Therapy: A single center experience. Cancer Treat Res Commun. 2020;25:100209.

Saqi A, Mukhopadhyay S, Butt Y, Doxtader E, Heymann JJ, Larsen BT, et al. E-cigarette or vaping product use-associated lung injury: What is the role of cytologic assessment? Cancer Cytopathol. 2020;128(6):371-380.

Li S, Kendall J, Park S, Wang Z, Alexander J, Moffitt A, et al. Copolymerization of single-cell nucleic acids into balls of acrylamide gel. Genome Res. 2020;30(1):49-61.

Rogers WS, Westblade LF, Soave R, Jenkins SG, Van Besien K, Singh HK, et al. Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020;71(7):1693-1700.

Zhang T, Na JH, Li S, Chen Z, Zhang G, Pang S, et al. Functional impact of cancer patient-associated Bcl-xL mutations. MedComm (Beijing). 2020;1(3):328-337.

Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, et al. Phase I study of the Lu-DOTA-Tyr-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2).

Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.